Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Oric Pharmaceuticals, Inc. |
|---|---|
| Ticker | ORIC |
| CIK | 0001796280 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 940,4 Mio. USD |
| Beta | 1,36 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -129,468,000 | -1.47 | 408,890,000 | 384,362,000 | |
| 2025-09-30 | 10-Q | -32,587,000 | -0.33 | 431,192,000 | 406,919,000 | |
| 2025-06-30 | 10-Q | -36,355,000 | -0.47 | 346,857,000 | 323,995,000 | |
| 2025-03-31 | 10-Q | -30,021,000 | -0.42 | 242,858,000 | 219,738,000 | |
| 2024-12-31 | 10-K | -127,847,000 | -1.83 | 274,142,000 | 243,122,000 | |
| 2024-09-30 | 10-Q | -34,566,000 | -0.49 | 302,070,000 | 273,994,000 | |
| 2024-06-30 | 10-Q | -31,963,000 | -0.45 | 328,906,000 | 302,400,000 | |
| 2024-03-31 | 10-Q | -25,011,000 | -0.37 | 350,786,000 | 328,645,000 | |
| 2023-12-31 | 10-K | -100,697,000 | -1.96 | 252,007,000 | 224,088,000 | |
| 2023-09-30 | 10-Q | -25,478,000 | -0.44 | 274,335,000 | 247,414,000 | |
| 2023-06-30 | 10-Q | -22,944,000 | -0.50 | 291,816,000 | 268,799,000 | |
| 2023-03-31 | 10-Q | -23,945,000 | -0.53 | 226,648,000 | 202,812,000 | |
| 2022-12-31 | 10-K | -89,122,000 | -2.25 | 247,178,000 | 222,351,000 | |
| 2022-09-30 | 10-Q | -24,829,000 | -0.63 | 237,997,000 | 214,819,000 | |
| 2022-06-30 | 10-Q | -20,287,000 | -0.51 | 259,684,000 | 236,870,000 | |
| 2022-03-31 | 10-Q | -23,159,000 | -0.59 | 275,062,000 | 253,079,000 | |
| 2021-12-31 | 10-K | -78,715,000 | -2.07 | 298,642,000 | 272,976,000 | |
| 2021-09-30 | 10-Q | -18,426,000 | -0.47 | 314,180,000 | 291,536,000 | |
| 2021-06-30 | 10-Q | -21,009,000 | -0.57 | 268,227,000 | 258,323,000 | |
| 2021-03-31 | 10-Q | -16,509,000 | 283,960,000 | 276,075,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | Piscitelli Dominic | Officer, Chief Financial Officer | Open Market Sale | -52,000 | 13.51 | -702,686.40 | -200,0% | |
| 2026-01-16 | Heyman Richard A. | Director | Open Market Sale | -3,500 | 12.00 | -42,016.10 | -12,0% | |
| 2026-01-16 | Heyman Richard A. | Director | Open Market Sale | -3,200 | 12.00 | -38,414.72 | -10,9% | |
| 2025-12-16 | Chacko Jacob | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -33,374 | 9.06 | -302,368.44 | -86,1% | |
| 2025-12-16 | Piscitelli Dominic | Officer, Chief Financial Officer | Open Market Sale | -10,720 | 9.06 | -97,127.49 | -27,6% | |
| 2025-12-16 | Multani Pratik S | Officer, Chief Medical Officer | Open Market Sale | -10,720 | 9.06 | -97,128.56 | -27,6% | |
| 2025-10-06 | Chacko Jacob | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -37,461 | 12.32 | -461,519.52 | -131,4% | |
| 2025-10-06 | Piscitelli Dominic | Officer, Chief Financial Officer | Open Market Sale | -11,000 | 14.52 | -159,718.90 | -45,5% | |
| 2025-10-01 | Chacko Jacob | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -53,001 | 12.05 | -638,805.15 | -181,8% | |
| 2025-09-30 | Chacko Jacob | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -34,538 | 12.01 | -414,749.57 | -118,0% | |
| 2025-09-22 | Chacko Jacob | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -125,000 | 10.80 | -1,349,937.50 | -384,2% | |
| 2025-06-23 | You Angie | Director | Open Market Purchase | 1,403 | 9.43 | 13,230.29 | +3,8% | |
| 2025-06-20 | You Angie | Director | Open Market Purchase | 26,597 | 9.39 | 249,668.70 | +71,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.